Understanding the High Prevalence of Diabetes in U.S. South Asians Compared with Four Racial/Ethnic Groups: The MASALA and MESA Studies

OBJECTIVE
We compared South Asians with four other race/ethnic groups in the U.S. to determine whether sociodemographic, lifestyle, or metabolic factors could explain the higher diabetes prevalence, and whether insulin resistance and β-cell dysfunction occurred at younger ages and/or lower adiposity levels compared with other groups.

RESEARCH DESIGN AND METHODS
Cross-sectional analysis of two community-based cohorts, the Mediators of Atherosclerosis in South Asians Living in America (MASALA) study and the Multi-Ethnic Study of Atherosclerosis (MESA); all participants had no known cardiovascular disease and were between 44 and 84 years of age. We compared 799 South Asians with 2,611 whites, 1,879 African Americans, 1,493 Latinos, and 801 Chinese Americans. Type 2 diabetes was classified by fasting plasma glucose ≥126 mg/dL or use of a diabetes medication. Insulin resistance was estimated by the homeostasis model assessment (HOMA) and β-cell function was measured by the HOMA-β model.

RESULTS
South Asians had significantly higher age-adjusted prevalence of diabetes (23%) than the MESA ethnic groups (6% in whites, 18% in African Americans, 17% in Latinos, and 13% in Chinese Americans). This difference increased further after adjusting for potential confounders. HOMA of insulin resistance (HOMA-IR) levels were significantly higher and HOMA-β levels were lower among South Asians compared with all other race/ethnic groups after adjusting for age and adiposity.

CONCLUSIONS
The higher prevalence of diabetes in South Asians is not explained by traditionally measured risk factors. South Asians may have lower β-cell function and an inability to compensate adequately for higher glucose levels from insulin resistance.

The prevalence of type 2 diabetes is increasing worldwide, with lifestyle and behavioral factors promoting obesity cited as the primary culprit (1). South Asians, including individuals originating from India, Pakistan, Nepal, Sri Lanka, and Bangladesh, have a very high prevalence of diabetes (2,3), and the South Asian
subcontinent is forecast to have the
highest burden of diabetes worldwide
by 2030 (4,5). Insulin resistance and ab-
normals of insulin secretion in pan-
creatic β-cells are the main defects that
lead to type 2 diabetes. South Asians
have high rates of insulin resistance
(6,7), but more recent studies have
shown that South Asians may have an
early decline in β-cell function as well
(8,9), a phenomenon with more genetic
underpinnings (10).

In a pilot study of a community-based
population of Asian Indians, we previ-
ously reported that the prevalence of di-
abetes was higher than in other U.S. ethnic
groups (11). Here we report the preva-
lence of impaired fasting glucose (IFG)
and diabetes in a larger community-
based South Asian population called the
Mediators of Atherosclerosis in South
Asians (MASALA) study. The MASALA
study was created with similar methods and measurements
as the Multi-Ethnic Study of Athero-
sclerosis (MESA) to make valid and ef-
cient cross-ethnic comparisons (12). We
sought to determine whether this higher
diabetes prevalence in South Asians was
explained by lifestyle factors, adiposity
measures, or other metabolic covariates,
including fasting insulin. We also exam-
ined the effect of age and adiposity on
insulin resistance and β-cell function in
South Asians compared with the four
MESA race/ethnic groups.

**RESEARCH DESIGN AND METHODS**

**MASALA Study Design and Setting**

The MASALA study is a community-
based cohort of South Asian men and
women from two clinical sites (San Fran-
cisco Bay Area at the University of Cal-
ifornia, San Francisco [UCSF], and the
greater Chicago area at Northwestern
University [NWU]). The baseline exami-
nation was conducted from October
2010 through March 2013. The institu-
tional review boards of UCSF and NWU
approved the MASALA study protocol.

**Eligibility Criteria**

Study methods have been previously re-
ported (12). In brief, to be eligible for the
MASALA study, participants had to
1) self-identify to be of South Asian ori-
gin and have at least three grandparents
born in one of the following countries: India, Pakistan, Bangladesh, Nepal, or Sri
Lanka; 2) be between 40 and 84 years of
age; and 3) have the ability to speak
and/or read English, Hindi, or Urdu.

We used identical exclusion criteria
to MESA (13), which included having a
physician-diagnosed heart attack, stroke,
transient ischemic attack, heart failure, angina, or use of nitroglycerin or those with a history of cardiovas-
cular procedures such as coronary
artery bypass graft surgery, angioplasty,
pacemaker or defibrillator implantation,
or any surgery on the heart or arteries.
Those with current atrial fibrillation or in active treatment for cancer were excluded. Those with
life expectancy <5 years due to a seri-
ous medical illness, with impaired cog-
nitive ability as judged by the reviewer,
planning to move out of the study re-
region in the next 5 years, or in a
nursing home or on a waiting list were
also excluded. Due to computed tomo-
ography scanner limitations, those
weighing >300 lbs were excluded.

**Clinical Measurements**

All visits were conducted by trained bi-
lingual study staff, and all consent forms
were translated into Hindi and Urdu. We
gathered information on participant de-
mographic data, tobacco use, alcohol
consumption, and medication use. In-
tentional exercise in metabolic equiva-
ents (MET)-minutes per week was
assessed using the Typical Week’s Phys-
ical Activity Questionnaire (14).

Seated resting blood pressure was
measured three times using an auto-
mated blood pressure monitor (V100 Vi-
tal Signs Monitor; GE Medical Systems,
Fairfield, CT), and the average of the last
two readings was used for analysis. Hy-
pertension was defined as self-reported
treatment for hypertension or a systolic
blood pressure ≥140 mmHg or diastolic
blood pressure ≥90 mmHg. Participant
weight was measured on a standard bal-
ance beam scale or digital weighing scale
and height using a stadiometer, and
BMI was calculated as weight in
kilograms divided by height in meters
squared. Waist circumference was mea-
sured using a flexible tape measure tape
at the site of maximum circumference
midway between the lower ribs and the
anterior superior iliac spine.

After a requested 12-h fast, blood tests
were obtained. Fasting plasma glucose
was measured by the glucose oxidase
method; total cholesterol, triglycerides,
and HDL cholesterol were measured by
enzymatic methods (Quest, San Jose,
CA, and Chicago, IL) and LDL cholesterol
was calculated (15). Diabetes was clas-
sified if a participant was using a glucose-
lowering medication or had a fasting
plasma glucose ≥126 mg/dL. IFG was de-
finned for those with fasting glucose be-
tween 100 and 125 mg/dL, and normal
plasma glucose was <100 mg/dL (16). Fasting
serum samples were batched for insulin
measured by the sandwich immunoassay
method (Roche Elecsys 2010; Roche Diag-
nostics, Indianapolis, IN). The homeosta-
sis model assessment of insulin resistance
(HOMA-IR) was used to measure insulin
resistance and calculated as insulin0
(µU/mL) × glucose0 (mmol/L)/22.5, and
HOMA-β was used to measure β-cell
function and was calculated as 20 ×
insulin0 (µU/mL)/glucose0 (mmol/L) −
3.5 (17). Individuals taking diabetes med-
ications were excluded from the analyses
of HOMA-IR and HOMA-β due to bias in
the measurement with treatment effects.

**MESA Study Methods**

The study design, eligibility, and meth-
ods for MESA have been previously pub-
lished (13). MESA includes individuals
from four racial/ethnic groups (whites,
African Americans, Latinos, and Chinese
Americans). We used data from the base-
line MESA examination (2000–2002) for
this analysis. Identical questionnaires
for sociodemographic characteristics and
physical activity and protocols for seated
blood pressure and anthropometry were
used as described above for the MASALA
study.

Serum glucose was measured from
fasting samples by the glucose oxidase
method (Ortho Clinical Diagnostics,
Johnson & Johnson). Serum insulin was
measured from baseline samples with the
Beckman Access assay. To harmonize
this insulin assay with newer-generation
assays with the Roche Elecsys assay that
were used in future MESA exams (as well
as the MASALA study), a calibration
study was performed to calculate a formula
for serum insulin values that correlated with
the Roche method. The calibration for-
mal is as follows: calibrated insulin =
1.656 + [0.208 × (Beckman Access assay
result × 6)]

Similar definitions were used for di-
abetes, impaired and normal fasting glu-
cose, and HOMA-IR and HOMA-β. We
excluded six MESA participants from
this analysis who had fasting glucose levels <64 mg/dL and were not taking diabetes medications since HOMA-β could not be calculated.

To have a similar age range of participants from both the MASALA and MESA studies, individuals in the MASALA study <44 years of age were excluded from this analysis, leaving a total of 799 South Asians who were compared with the four MESA racial/ethnic groups (2,611 whites, 1,879 African Americans, 1,493 Latinos, and 801 Chinese Americans).

### Statistical Analyses

Baseline characteristics of the MASALA participants and each of the MESA racial/ethnic groups were summarized using descriptive statistics as appropriate. The crude, age-/site-/sex-adjusted, and fully adjusted prevalence of normal, IFG, and diabetes within each race/ethnicity and for each sex was estimated using multinomial logistic regression models, followed by regression standardization (18). Fully adjusted models included age, sex, clinical site, educational attainment, family income, current smoking, alcohol use, exercise, BMI, waist circumference, HDL cholesterol, triglycerides, hypertension, and fasting insulin. We purposely did not adjust for HOMA-IR or HOMA-β because fasting glucose is a common component of these surrogate measures and the outcome of this analysis, complicating interpretation.

Average HOMA-IR and HOMA-β levels for each racial/ethnic group were estimated using linear models adjusting for age, sex, site, BMI, waist circumference, fasting glucose, smoking status, physical activity levels, and alcohol use. Because HOMA-IR and HOMA-β are right skewed, these measures were log-transformed for analysis, and then the results back-transformed to the measured scale. Linear models adjusting for site and sex were also used to examine the association between the HOMA measures and age among participants not using diabetes medications within each racial/ethnic group. Specifically, we regressed log-transformed HOMA values on a three-knot restricted cubic spline in age and then plotted the back-transformed fitted values against age. We also used this approach to examine the associations between HOMA and BMI and waist circumference, by race/ethnicity and then by sex, adjusting for age and site. Tests for interaction were used to determine whether the associations between HOMA and age, BMI, and waist circumference differed by race/ethnicity or sex. Scatter plots were used to assess the potential influence of outliers.

All analyses were conducted in SAS version 9.3 (SAS Institute, Cary, NC) and Stata version 12.1 (Stata Corporation, College Station, TX).

### RESULTS

Table 1 shows the baseline characteristics of the MASALA and MESA participants by race/ethnic group. South Asians were significantly younger than the MESA groups and had higher educational

---

**Table 1—Baseline characteristics of MASALA and MESA participants by race/ethnicity**

|                          | South Asian, n = 799 | White, n = 2,611 | African American, n = 1,879 | Latino, n = 1,493 | Chinese American, n = 801 |
|--------------------------|----------------------|------------------|-------------------------------|-------------------|---------------------------|
| Male sex (%)             | 53                   | 48               | 45                            | 48                | 48                        |
| Age (years)              | 57 ± 9               | 63 ± 10          | 62 ± 10                       | 61 ± 10           | 61 ± 10                   |
| Immigrants to U.S. (%)   | 99                   | 7                | 9                             | 69                | 96                        |
| Education ≥ Bachelor (%) | 87                   | 50               | 34                            | 10                | 39                        |
| Family income ≥ $75,000 (%) | 71           | 36               | 16                            | 7                 | 17                        |
| Current smoker (%)       | 3                    | 12               | 18                            | 14                | 6                         |
| Alcohol use ≥ 1 drink/week (%) | 33     | 64               | 52                            | 47                | 21                        |
| Exercise (MET-min/week)* | 945 (330–1837)       | 1,852 (874–3,360) | 1,665 (630–3,570)            | 1,204 (424–2,730) | 1,260 (607–2,422)         |
| BMI (kg/m²)              | 26 ± 4               | 28 ± 5           | 30 ± 6                        | 29 ± 5            | 24 ± 3                    |
| Waist circumference (cm) | 93 ± 10              | 98 ± 14          | 101 ± 15                      | 101 ± 13          | 87 ± 10                   |
| Systolic blood pressure (mmHg) | 126 ± 16  | 124 ± 20         | 132 ± 22                      | 127 ± 22          | 125 ± 22                  |
| Diastolic blood pressure (mmHg) | 73 ± 10  | 70 ± 10          | 75 ± 10                       | 72 ± 10           | 72 ± 10                   |
| Hypertension (%)†        | 43                   | 39               | 59                            | 42                | 37                        |
| LDL cholesterol (mmol/L) | 2.87 ± 0.83          | 3.03 ± 0.78      | 3.00 ± 0.85                   | 3.10 ± 0.85       | 2.97 ± 0.75               |
| HDL cholesterol (mmol/L)* | 1.24 (1.03–1.50)   | 1.29 (1.06–1.58) | 1.29 (1.06–1.58)              | 1.16 (1.01–1.40) | 1.24 (1.03–1.45)          |
| Triglycerides (mmol/L)*  | 1.34 (1.00–1.78)     | 1.29 (0.87–1.85) | 1.02 (0.74–1.39)              | 1.52 (1.08–2.17) | 1.40 (0.98–1.94)          |
| Fasting glucose (mmol/L)* | 5.38 (5.00–6.05)   | 4.83 (4.50–5.27) | 5.05 (4.61–5.66)              | 5.11 (4.66–5.77) | 5.11 (4.77–5.61)          |
| Fasting insulin (pmol/L)* | 60 (42–88)           | 45 (33–66)       | 53 (37–77)                    | 57 (39–83)        | 46 (36–65)                |
| HOMA-IR (µIU/mL, mmol/L)*‡ | 2.3 (1.5–3.5)       | 1.6 (1.1–2.4)    | 1.9 (1.3–2.9)                 | 2.0 (1.4–3.2)     | 1.8 (1.3–2.6)             |
| HOMA-β (µIU/mL, mmol/L)*‡ | 111 (75–156)        | 118 (86–167)     | 118 (82–171)                  | 124 (85–183)      | 101 (75–144)              |
| Diabetes medication use (%) | 18                  | 4                | 14                            | 14                | 10                        |

---

* Median (interquartile range) shown for skewed variables. † Hypertension defined by systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg or use of an antihypertensive medication. Excludes those using any diabetes medications. § IFG defined by fasting glucose 100–125 mg/dL; diabetes defined by fasting plasma glucose ≥126 mg/dL and/or use of a diabetes medication.
Higher Diabetes in South Asians

Diabetes Care

Table 2—Prevalence of IFG and diabetes in five ethnic groups with sequential adjustment for covariates, MASALA and MESA studies

| Overall populations | South Asian, n = 799 | White, n = 2,611 | African American, n = 1,879 | Latino, n = 1,493 | Chinese American, n = 801 |
|---------------------|----------------------|------------------|-----------------------------|------------------|---------------------------|
| Crude DM prevalence (%) | 21.1 (18.3–24.0) | 6.0 (5.1–7.0)† | 17.7 (15.9–19.4) | 17.7 (15.7–19.6) | 13.1 (10.8–15.4)† |
| Age-, sex-, and site-adjusted DM prevalence (%) | 23.2 (18.3–28.1) | 5.9 (4.9–6.8)† | 18.0 (15.9–20.0) | 17.0 (14.9–19.3) | 13.2 (10.6–15.8)† |
| Fully adjusted DM prevalence (%)† | 26.7 (21.2–32.3) | 6.3 (5.3–7.3)† | 16.4 (14.5–18.3)* | 14.5 (12.6–16.3) | 16.0 (12.9–19.1)† |
| Men | n = 422 | n = 1,256 | n = 837 | n = 720 | n = 388 |
| Crude IFG prevalence (%) | 27.0 (22.8–31.2) | 13.6 (11.7–15.5)† | 17.4 (14.9–20.0)† | 17.5 (14.7–20.3)* | 21.1 (17.1–25.2) |
| Crude DM prevalence (%) | 26.8 (22.5–31.0) | 7.6 (6.1–9.0)† | 19.5 (16.8–22.2)* | 19.0 (16.2–21.9)* | 13.9 (10.5–17.4)† |
| Age- and site-adjusted DM prevalence (%) | 31.0 (23.5–38.4) | 7.0 (5.5–8.4)† | 18.6 (15.6–21.5)* | 20.5 (16.9–24.1)* | 14.3 (10.4–18.2)† |
| Fully adjusted DM prevalence (%)† | 32.5 (24.4–40.6) | 7.1 (5.6–8.6)† | 17.7 (14.8–20.5)* | 17.8 (14.6–21.1)* | 18.8 (13.9–23.8)* |
| Women | n = 377 | n = 1,355 | n = 1,042 | n = 773 | n = 413 |
| Crude IFG prevalence (%) | 21.2 (17.1–25.3) | 9.0 (7.5–10.5)† | 12.7 (10.6–14.7)* | 13.6 (11.2–16.0)* | 13.3 (10.0–16.6)* |
| Crude DM prevalence (%) | 14.8 (11.3–18.4) | 4.6 (3.5–5.8)† | 16.2 (14.0–18.5) | 16.4 (13.8–19.0) | 12.3 (9.2, 15.5) |
| Age- and site-adjusted DM prevalence (%) | 15.5 (9.5–21.5) | 4.8 (3.6–6.0)† | 17.4 (14.6–20.3) | 14.2 (11.5–16.8) | 12.2 (8.7–15.8) |
| Fully adjusted DM prevalence (%)† | 22.4 (14.3–30.4) | 5.6 (4.2–6.9)† | 15.2 (12.7–17.7) | 11.7 (9.5–13.8)* | 12.9 (9.2–16.7)* |

Data are presented for the overall study populations, then separately by sex. First data are presented as crude rates and then with age, sex, and site adjustment and finally with full covariate adjustment. DM, diabetes. *0.001 ≤ P < 0.05 for comparison with South Asians. †P < 0.001 for comparison with South Asians. ‡Adjusted for age, sex, clinical site, education, family income, smoking, alcohol use, exercise, BMI, waist circumference, HDL cholesterol, triglycerides, hypertension, and fasting insulin.

Table 2 shows the prevalence of diabetes comparing South Asians to each of the MESA race/ethnic groups overall and by sex. After adjusting for age, sex, and study site, there was a larger difference in diabetes prevalence between the South Asians (23%) and the other groups. Further adjustment for potential explanatory variables that could explain the association between race/ethnicity and diabetes, including education, family income, smoking, alcohol use, exercise, BMI, waist circumference, HDL, triglycerides, hypertension, and fasting insulin, increased the adjusted prevalence of diabetes in South Asians (27%) and widened the differences between South Asians and each race/ethnicity group. In sex-stratified analyses, South Asian men had a significantly higher prevalence of IFG and diabetes than men and women in all other ethnic groups. In unadjusted analyses, South Asian women had a significantly higher prevalence of IFG than women in other ethnic groups, but had a similar prevalence of diabetes compared with African American, Latino, and Chinese American women. In fully adjusted analyses for women, South Asian women had a

Figure 1—Median (95% CI) HOMA-IR and HOMA-β values adjusted by sex, age, clinical site, fasting glucose level, BMI, waist circumference, physical activity levels, smoking, and alcohol use; excludes those on any diabetes medications; the MASALA and MESA studies. *P < 0.001 in comparison to South Asians.
higher diabetes prevalence compared with all other groups except for African Americans. Within each race/ethnic group, after full covariate adjustment, men had a significantly higher diabetes prevalence compared with women.

Figure 1 displays the adjusted medians for HOMA-IR and HOMA-β by race/ethnic group among participants who were not taking diabetes medications. South Asians had a higher HOMA-IR and lower HOMA-β compared with the other race/ethnic groups, and this difference persisted after adjusting for their main determinants, including fasting glucose value. The only adjusted interethnic comparison that was not significantly different was between South Asians and Chinese Americans for HOMA-IR outcome. Figure 2 shows the spline curves for insulin resistance (A) and β-cell function (B) over the age distribution for each race/ethnic group, adjusted for sex and clinical site. Race/ethnicity significantly modified the association between age and insulin resistance (P for interaction =0.001), but the association between age and HOMA-β was similar for each race/ethnic group (P for interaction =0.27). Additionally, in all ethnic groups, the association between age and HOMA-IR was stronger in men than in women (P for interaction =0.02). In contrast, although South Asians had the lowest levels of HOMA-β compared with all other groups, the gradual decline in β-cell function by age was common to all race/ethnic groups and to both men and women.

The association between BMI and HOMA-IR showed a log-linear relationship.
in most race/ethnic groups, but South Asians had a distinct nonlinear pattern, with faster increases in HOMA-IR in the region with BMI <30 kg/m² but slower increases above that level (P for interaction <0.001) (Fig. 3A). On average, the trend in HOMA-IR was steepest for Chinese Americans. HOMA-β was lowest among South Asians at any given BMI (P for interaction <0.001) (Fig. 3B), and on average, the trend was steepest among Chinese Americans. These relationships were more significant in men than women in all race/ethnic groups (P for interaction by sex <0.001). Plotting HOMA-IR and HOMA-β against waist circumference revealed similar results in the four MESA ethnic groups but somewhat different patterns in the South Asians (Fig. 3, lower panels). In particular, trends among South Asians in both metabolic measures accelerated across the range of waist circumference, in contrast to their decelerating trends in the region with BMI >30 kg/m².

**CONCLUSIONS**

In a large community-based sample of South Asians without existing cardiovascular disease, we confirmed that South Asians have a significantly higher prevalence of prediabetes and diabetes than four other U.S. ethnic groups (11). Additionally, South Asian men have the highest diabetes prevalence overall, whereas South Asian women have a higher diabetes prevalence than white and Chinese American women but a similar prevalence to African American and Latino women. The broad disparity in diabetes among South Asians compared with the other ethnic groups was further widened after adjusting for all potential correlates of diabetes. South Asians have higher HOMA-IR levels and lower HOMA-β than all other ethnic groups after adjusting for age and adiposity. These findings suggest that South Asians may have lower β-cell function and are unable to compensate for higher glucose levels due to insulin resistance, which ultimately leads to the dramatically higher rates of type 2 diabetes.

South Asians are known for having high type 2 diabetes prevalence in native (19,20) and diaspora settings (2,21,22). Studies that have directly compared diabetes prevalence in South Asians with other ethnic groups in North America have found higher diabetes rates among South Asians than most other ethnic groups (23–25). Similarly, we found that middle- to older-aged South Asians in the U.S. with higher socioeconomic attainment than South Asians living in other Western countries still have a significantly higher IFG and diabetes prevalence compared with

![Figure 3](image-url)
four other ethnic groups. Adjusting for sociodemographic, lifestyle, and metabolic covariates only enhanced the difference between South Asians and other ethnic groups, suggesting that other unmeasured factors, including biologic differences in the mechanisms of diabetes and a higher genetic burden (26), may be responsible.

We compared insulin resistance patterns by age and adiposity and found that South Asians have higher HOMA-IR levels compared with other ethnic groups. Although no prior studies have compared as many ethnic groups directly with South Asians, several have reported that South Asians have higher basal insulin levels and a higher insulin response to a glucose load than Europeans (27) and Chinese (28–30). Moreover, studies have found that a higher percentage of body fat and abdominal adiposity in South Asians (31) does not appear to explain these high levels of insulin resistance (32,33).

We also found that South Asians have lower β-cell function at all ages than other ethnic groups, although the decline with age appears to be similar to other groups. Whereas others have found reduced β-cell function in Asian Indians (9), others have noted that β-cell function declines more rapidly with age in Asian Indians than other ethnic groups (28). It is unclear whether there may be a genetic predisposition to lower β-cell mass and function, earlier β-cell loss from environmental factors, or quicker β-cell exhaustion from higher levels of insulin resistance or a complex combination of all of these factors among South Asians (34).

There was a notable difference in the spline curves between BMI and waist circumference for both HOMA-IR and HOMA-β that was observed only among South Asians. Increases in HOMA-IR and HOMA-β plateau in the region above BMI of 30 kg/m², whereas both measures continue to increase across the range of waist circumference values. This inconsistency in the associations between these two surrogate measures of body adiposity may be due to sparse data with few South Asians having BMI >30 kg/m², but also underscores the findings of early studies where central adiposity was much more closely linked to insulin resistance and diabetes than BMI in South Asians (35). This finding also provides further evidence that for assessing metabolic risk, waist circumference is a better measure of adiposity than BMI among South Asians.

Although we were able to compare glycemic status between South Asians and four other well-phenotyped U.S. ethnic groups, we were limited to using fasting glucose and insulin measures and did not have more sophisticated measures of insulin resistance or β-cell function. The cross-sectional design also limits us from comparing the relative strengths of insulin resistance or β-cell function as risk factors for diabetes. We also did not have comparable measures of dietary intake in both studies and were unable to determine whether diet may explain some of the ethnic differences in diabetes prevalence. Although the South Asians in MASALA are representative of middle-aged South Asians in the U.S. (12), the findings may not generalize to all South Asians in native or other diaspora settings with very different socioeconomic and environmental exposure.

In conclusion, South Asians have a significantly higher prediabetes and diabetes prevalence than other U.S. ethnic groups, which is not explained by known risk factors. South Asians have significantly higher insulin resistance and lower β-cell function than other ethnic groups. The biological and genetic mechanisms underlying these differences deserve further study. Prospective follow-up of the MASALA study cohort can assess whether insulin resistance and β-cell function explain the higher diabetes rates in South Asians.

**Funding.** The MASALA study was supported by the National Institutes of Health (NIH) Grant 1R01-HL-093009. Data collection at UCSF was also supported by NIH/National Center for Research Resources UCSF-CTSI Grant UL1-RR-024131. The MESA study was funded by contracts N01-HC-95159, N01-HC-95169, and N01-HC-95166 from the National Heart, Lung, and Blood Institute. The sponsors for both studies did not play a significant role in the analysis, interpretation, and presentation of these results.

**Duality of Interest.** No potential conflicts of interest relevant to this article were reported.

**Author Contributions.** A.M.K. conceived the project, researched data, and wrote the manuscript. D.H. contributed to the interpretation of the results and reviewed and edited the manuscript. E.V. supervised and contributed to the data analyses and reviewed and edited the manuscript. S.K.E. performed the data analysis and reviewed and edited the manuscript. K.L. and M.I.B. reviewed and edited the manuscript. S.S.D. and F.Q. collected data and reviewed and edited the manuscript. N.R.K. contributed to the interpretation of the results and reviewed and edited the manuscript. A.M.K. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

**Prior Presentation.** This study was presented as a moderated poster at the American Heart Association Epidemiology and Prevention/Nutrition, Physical Activity, and Metabolism 2014 Scientific Sessions, San Francisco, CA, 18–21 March 2014.

**References**

1. Hu FB. Globalization of diabetes: the role of diet, lifestyle, and genes. Diabetes Care 2011; 34:1249–1257
2. Misra R, Patel T, Kotha P, et al. Prevalence of diabetes, metabolic syndrome, and cardiovascular risk factors in US Asian Indians: results from a national study. J Diabetes Complications 2009;24:145–153
3. Nair M, Ali MK, Ayaj VS, et al. CARRS Surveillance study: design and methods to assess burdens from multiple perspectives. BMC Public Health 2012;12:701
4. Shaw JE, Sicree RA, Zimet PD. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010;87:4–14
5. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047–1053
6. McKeigue PM. Metabolic consequences of obesity and body fat pattern: lessons from migrant studies. Ciba Found Symp 1996;201:54–64; discussion 64–7, 188–193
7. Gujral UP, Pradeepa R, Weber MB, Narayan KM, Mohan V. Type 2 diabetes in South Asians: similarities and differences with white Caucasian and other populations. Ann N Y Acad Sci 2013;1281:51–63
8. Mohan V, Amutha A, Ranjani H, et al. Associations of β-cell function and insulin resistance with youth-onset type 2 diabetes and prediabetes among Asian Indians. Diabetes Technol Ther 2013;15:315–322
9. Staimer LR, Weber MB, Ranjani H, et al. Evidence of reduced β-cell function in Asian Indians with mild dysglycemia. Diabetes Care 2013;36:2772–2778
10. Florez JC. Newly identified loci highlight beta cell dysfunction as a key cause of type 2 diabetes: where are the insulin resistance genes? Diabetologia 2008;51:1100–1110
11. Kanaya AM, Wassel CL, Mathur D, et al. Prevalence and correlates of diabetes in South Asian Indians in the United States: findings from the Metabolic Syndrome and Atherosclerosis in South Asians Living in America study and the Multi-Ethnic Study of Atherosclerosis. Metab Syndr Relat Disord 2010;8:157–164
12. Kanaya AM, Kandula N, Herrington D, et al. Mediators of Atherosclerosis in South Asians Living in America (MASALA) Study: objectives, methods, and cohort description. Clin Cardiol 5 November 2013 [Epub ahead of print]
13. Bild DE, Bluemke DA, Burke GL, et al. Multi-ethnic study of atherosclerosis: objectives and design. Am J Epidemiol 2002;156:871–881
14. Ainsworth BE, Irwin ML, Addy CL, Whitt MC, Stolarczyk LM. Moderate physical activity patterns of minority women: the Cross-Cultural Activity Participation Study. J Womens Health Gend Based Med 1999;8:805–813
15. Friedewald WTL, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499–502
16. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2004;27(Suppl. 1):S5–S10
17. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412–419
18. Lane PW, Nelder JA. Analysis of covariance and standardization as instances of prediction. Biometrics 1982;38:613–621
19. Mohan V, Deepa M, Deepa R, et al. Secular trends in the prevalence of diabetes and impaired glucose tolerance in urban South India—the Chennai Urban Rural Epidemiology Study (CURES-17). Diabetologia 2006;49:1175–1178
20. Ramachandran A, Mary S, Yamuna A, Murugesan N, Snehalatha C. High prevalence of diabetes and cardiovascular risk factors associated with urbanization in India. Diabetes Care 2008;31:893–898
21. Tillin T, Hughes AD, Godsland IF, et al. Insulin resistance and truncal obesity as important determinants of the greater incidence of diabetes in Indian Asians and African Caribbeans compared with Europeans: the Southall And Brent Revisited (SABRE) cohort. Diabetes Care 2013;36:383–393
22. Bhopal R, Hayes L, White M, et al. Ethnic and socio-economic inequalities in coronary heart disease, diabetes and risk factors in Europeans and South Asians. J Public Health Med 2002;24:95–105
23. Karter AJ, Schillinger D, Adams AS, et al. Elevated rates of diabetes in Pacific Islanders and Asian subgroups: the Diabetes Study of Northern California (DISTANCE). Diabetes Care 2013;36:574–579
24. Lee JW, Brancati FL, Yeh HC. Trends in the prevalence of type 2 diabetes in Asians versus whites: results from the United States National Health Interview Survey, 1997–2008. Diabetes Care 2011;34:353–357
25. Anand SS, Yusuf S, Vuksan V, et al. Differences in risk factors, atherosclerosis, and cardiovascular disease between ethnic groups in Canada: the Study of Health Assessment and Risk in Ethnic groups (SHARE). Lancet 2000;356:279–284
26. Khan NA, Wang H, Anand S, et al. Ethnicity and sex affect diabetes incidence and outcomes. Diabetes Care 2011;34:96–101
27. Mohan V, Sharp PS, Cloke HF, Burrin JM, Schumner B, Kohner EM. Serum immunoreactive insulin responses to a glucose load in Asian Indians and European type 2 (non-insulin-dependent) diabetic patients and control subjects. Diabetologia 1986;29:233–237
28. Dowse GK, Qin H, Collins VR, Zinmet PZ, Albetti KG, Gareebo H; The Mauritius NCD Study Group. Determinants of estimated insulin resistance and beta-cell function in Indian, Creole and Chinese Mauritians. Diabetes Res Clin Pract 1990;10:265–279
29. Liew CF, Seag ES, Yeo KP, Lee KO, Wise SD. Lean, non-diabetic Asian Indians have decreased insulin sensitivity and insulin clearance, and raised leptin compared to Caucasians and Chinese subjects. Int J Obes Relat Metab Disord 2003;27:784–789
30. Hughes K, Aw TC, Kuperan P, Choo M. Central obesity, insulin resistance, syndrome X, lipoprotein(a), and cardiovascular risk in Indians, Malays, and Chinese in Singapore. J Epidemiol Community Health 1997;51:394–399
31. Deurenberg P, Yap M, van Staveren WA. Body mass index and percent body fat: a meta analysis among different ethnic groups. Int J Obes Relat Metab Disord 1998;22:1164–1171
32. Chandalia M, Abate N, Garg A, Stray Gundersen J, Grundy SM. Relationship between generalized and upper body obesity to insulin resistance in Asian Indian men. J Clin Endocrinol Metab 1999;84:2329–2335
33. Forouhi NG, Jenkinson G, Thomas EL, et al. Relation of triglyceride stores in skeletal muscle cells to central obesity and insulin sensitivity in European and South Asian men. Diabetologia 1999;42:932–935
34. Taylor R. Pathogenesis of type 2 diabetes: tracing the reverse route from cure to cause. Diabetologia 2008;51:1781–1789
35. McKiegue PM, Shah B, Marmot MG. Relation of central obesity and insulin resistance with high diabetes prevalence and cardiovascular risk in South Asians. Lancet 1991;337:382–386